ALBUQUERQUE, New Mexico – VisionQuest Biomedical LLC has announced today that it has executed a contract with TreVia Digital Health (TreVia) for use of their cloud-based technology designed to treat and manage diabetes using telemedicine and other care coordination tools. With TreVia’s diabetes telemedicine solution, VisionQuest aims to improve its wide-scale teleretinal screening program, EyeStarTM, improving medical outcomes, quality of care, and reducing unnecessary procedural and therapeutic costs. Dr. Peter Soliz, PhD, CEO and founder of VisionQuest Biomedical stated today, “With TreVia’s web-based diabetic retinal screening platform, our program now has the most advanced healthcare tools. With this solution we will streamline our teleretinal screening program to provide rapid triage, earlier detection of damaging eye disease and prevention of blindness from the devastating long-term effects of diabetes.”
VisionQuest’s role is to further expand the EyeStarTM Retinal Screening System using the TreVia software as the core of its network communication, to provide quick turn-around and easy access that will provide physicians with new and rapid insights into their patient’s retinal health. The EyeStarTM teleretinal information as delivered through TreVia’s system will lead to early detection of retinal disease, combined with convenient access and use for providers and patients. It will help physicians better manage their patient’s chronic eye diseases such as diabetic retinopathy, age-related macular degeneration and glaucoma, as well as give PCPs additional clues about diabetes, hypertension, and cardiovascular disease (CVD). Results will be available faster and through the internet – lending access where and when needed so the entire care team can effectively engage in the patient’s health status.
The license arrangement will also be used to expand VisionQuest’s teleretinal screening program in northern Mexico at Las Clinicas de Azucar. Using the Trevia as its backbone, the teams at the Las Clinicas clinics plan to screen the entire patient population of 5000 individuals with diabetes by the end of 2015.
By harnessing the latest technology advancements, including real- time events and a guarantee of image delivery, TreVia ensures the highest degree of security, safety, and reliability when it comes to the exchange of patient information between providers.
“In an industry where communication and collaboration are often fragmented, we are reinventing diabetes care by providing higher quality preventative care and a convenient process for retinal screenings and care coordination across the care team and for the patient” added Maureen Peszko, President and COO of TreVia Digital Health. “It is our mission to ultimately provide better patient outcomes by advancing a new level of digital collaboration that enables us to detect issues early, preserve vision, reduce complex procedures and lower healthcare costs.”
About VisionQuest Biomedical LLC
VisionQuest Biomedical was formed in 2007 to test advanced medical imaging technologies in clinical environments for the purpose of making these advances readily available to clinics at large. VisionQuest i-Rx, Inc. is its sister company, established in 2012 for commercial screening products developed under the NIH Small Business Innovative Research program.
VisionQuest's first objective is to transition technologies developed by the founder and CEO of VisionQuest, Dr. Peter Soliz. Since 1996, Dr. Soliz has been developing ophthalmic imaging technologies, including a low-priced, portable retinal camera and software for automatic detection of retinal lesions in patients with diabetic retinopathy.
VisionQuest is in the process of securing private and federal funding to demonstrate the effectiveness of these new technologies for early detection of ocular disease. The focus is on low-cost, portable imaging technology for use in screening of high-risk populations for diabetic retinopathy, hypertensive retinopathy, glaucoma, and age-related macular degeneration. Software for automatic detection of markers for these diseases has been demonstrated in its research. VisionQuest has also developed and is now testing a device for early detection of peripheral neuropathy (diabetic foot). Using infrared technology, this device detects early signs of neuropathy before it is apparent to the primary care physician.
About TreVia Digital Health
Headquartered in Overland Park, Kansas, TreVia Digital Health provides technology-enabled services, including digital diabetic retinopathy screenings, for the prevention of diabetic complications to empower physicians, health organizations, payers, retailers and patients with solutions and tools so they can take a more active, collaborative role and measurably impact diabetes outcomes, the patient experience and the cost of treating diabetes. Through its telemedicine platform, TreVia increases provider collaboration, improves quality of care and lowers costs to achieve better clinical outcomes and efficient use of healthcare dollars. TreVia’s technology screens for diabetic retinopathy, macular degeneration, glaucoma and other ocular diseases. TreVia detects issues early preserving eye health, reducing complicated procedures and lowering health care costs.
